Chemotherapy plus bevacizumab vs chemoimmunotherapy for metastatic colorectal cancer: Real-world analysis

Table 2 Univariate and multivariate Cox analysis of the effect of prognostic factors in the original cohort (progression-free survival)

Dependent: Survival (PFS/30, status PFS)		All	HR (univariable)	HR (multivariable)
Gender	Male	90 (61.2)	-	-
	Female	57 (38.8)	0.83 (0.57-1.21, P = 0.335)	-
Age (year)	≤ 60	75 (51.0)	-	-
	> 60	72 (49.0)	1.02 (0.71-1.48, P = 0.915)	-
ECOG score	0-1	135 (91.8)	-	-
	2	12 (8.2)	1.68 (0.88-3.23, P = 0.117)	-
Primary tumor location	Right colon	49 (33.3)	-	-
	Left colon and rectum	98 (66.7)	1.11 (0.76-1.64, P = 0.587)	-
No. of metastatic organs	1	88 (59.9)	-	-
	≥ 2	59 (40.1)	1.39 (0.96-2.02, P = 0.082)	1.13 (0.76-1.67, P = 0.550)
Liver metastasis	No	64 (43.5)	-	-
	Yes	83 (56.5)	1.33 (0.92-1.94, P = 0.133)	-
Lung metastasis	No	105 (71.4)	-	-
	Yes	42 (28.6)	1.03 (0.68-1.56, P = 0.891)	-
RAS	Wild type	22 (15.0)	-	-
	Mutation	28 (19.0)	1.86 (0.98-3.53, P = 0.057)	1.95 (1.01-3.75, P = 0.045)
	Unknown	97 (66.0)	1.48 (0.87-2.53, P = 0.152)	1.65 (0.95-2.86, P = 0.076)
Group	Control group	107 (72.8)	-	-
	Experimental group	40 (27.2)	0.56 (0.36-0.88, P = 0.011)	0.55 (0.35-0.87, P = 0.011)

n = 148, events = 115, Likelihood ratio test = 12.91 on 4 df (P = 0.012). PFS: Progression-free survival; HR: Hazard ratio; ECOG: Eastern Cooperative Oncology Group.